Neuronetics Enhances Employee Engagement with New Inducement Awards
Neuronetics, Inc. (NASDAQ: STIM) recently made a significant move to strengthen its workforce and employee retention strategy by issuing inducement awards to a new employee. This initiative aligns with the company's dedication to fostering a motivated and committed team, essential for ongoing innovation in the field of mental health treatment.
Understanding the Inducement Awards
According to the guidelines outlined in NASDAQ Listing Rule 5635(c)(4), the awards were sanctioned by the company’s Compensation Committee. This structured approach assures that the awards serve as material inducements to secure the commitment of the new employee.
Details of the Performance Restricted Stock Units (PRSUs)
The inducement consisted of performance restricted stock units designed to vest over a specified schedule. For instance, the newly appointed employee, Bill Leonard, has been granted a total of 50,000 PRSUs. These units have a vested interest in maintaining both commitment and performance within Neuronetics. The vesting process will occur in three equal intervals, specifically on the dates of December 31, 2025, December 31, 2026, and December 31, 2027, contingent on the employee’s continued service with the company or its partner, Greenbrook TMS Inc., until the first vesting date.
About Neuronetics, Inc.
Neuronetics is at the forefront of mental health innovation, advocating for the importance of mental wellness alongside physical health. As a leading player in neuroscience, Neuronetics specializes in developing effective treatments that exceed traditional expectations. The company’s flagship solution, the NeuroStar Advanced Therapy, emerges as a non-invasive, non-drug approach, ensuring improvements in the quality of life for patients grappling with neurohealth conditions.
NeuroStar Therapy: A Beacon of Hope
The NeuroStar Advanced Therapy is distinguished as the leader in transcranial magnetic stimulation (TMS) therapy for adults experiencing major depressive disorder (MDD). With an impressive record of over 6.9 million treatments administered, this innovative therapy is bolstered by the most extensive clinical data set for any TMS system targeting depression. The data include insights from the world’s largest depression outcomes registry, which portrays the efficacy and safety of the treatment.
Greenbrook's Role in Treatment Delivery
Alongside Neuronetics, Greenbrook TMS Inc. operates numerous treatment centers across the country, facilitating access to NeuroStar Advanced Therapy and Spravato, a treatment option for patients with treatment-resistant depression. Greenbrook has successfully delivered over 1.68 million treatments to more than 51,000 patients, providing essential support for those in need.
Contacting Neuronetics
For interest in investor relations, you may reach out to Mike Vallie or Mark Klausner through ICR Healthcare at 443-213-0499. Email inquiries can be directed to ir@neuronetics.com.
For media inquiries, EvolveMKD is available at 646-517-4220 or via email at NeuroStar@evolvemkd.com.
Frequently Asked Questions
What are inducement awards?
Inducement awards are incentives given to new employees as a way to encourage them to join and remain with a company. These can include stock options or performance units.
How does the vesting of PRSUs work?
Performance restricted stock units (PRSUs) typically vest over time, meaning the employee will earn the units gradually, usually contingent on their ongoing employment and performance.
What is the significance of NeuroStar Advanced Therapy?
NeuroStar Advanced Therapy is a leading non-invasive treatment option for major depressive disorder, providing hope to those who have not benefited from traditional medication.
Who is Greenbrook TMS Inc.?
Greenbrook TMS Inc. operates treatment centers that provide TMS therapies, including the NeuroStar system, and work in conjunction with Neuronetics to deliver mental health solutions.
How can I contact Neuronetics for investment inquiries?
Investors can contact Mike Vallie or Mark Klausner at ICR Healthcare via phone at 443-213-0499 or email at ir@neuronetics.com.
